Glomerular diseases: membranous nephropathy-a modern view, Clin J Am Soc Nephrol, vol.9, pp.609-616, 2014. ,
Prognosis of untreated patients with idiopathic membranous nephropathy, N Engl J Med, vol.8, pp.85-89, 1993. ,
, Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis, Kidney Int, issue.2, pp.186-197, 2012.
M-type phospholipase A2 receptor as target antigen in idiopathic MN, N Engl Med J, vol.361, pp.11-21, 2009. ,
Antiphospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy, J Am Soc Nephrol, vol.26, pp.2545-2558, 2015. ,
URL : https://hal.archives-ouvertes.fr/inserm-02193793
Anti-phospholipase A2 receptor antibodies correlate with clinical status in primary membranous nephropathy, Clin J Am Soc Nephrol, vol.6, pp.1286-1291, 2011. ,
Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy, J Am Soc Nephrol, vol.25, pp.1357-1366, 2014. ,
Association of anti-PLA2R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy, Clin J Am Soc Nephrol, vol.7, pp.1386-1392, 2014. ,
Pre-transplant phospholipase A2 receptor autoantibody concentration is associated with clinically significant recurrence of membranous nephropathy post-kidney transplantation, Clin Transplant, vol.30, pp.461-469, 2016. ,
Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up, J Am Soc Nephrol, vol.28, pp.348-358, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01490466
Rituximab or cyclosporine in the treatment of membranous nephropathy, N Engl J Med, vol.381, pp.36-46, 2019. ,
A proposal for a serology-based approach to membranous nephropathy, J Am Soc Nephrol, vol.28, pp.421-430, 2017. ,
Rituximab for idiopathic membranous nephropathy: who can benefit?, Clin J Am Soc Nephrol, vol.1, pp.738-748, 2006. ,
The role of PLA2R antibody in treatment of membranous nephropathy, Kidney Int Rep, vol.3, pp.498-501, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-02380946
A case report of remission of refractory membranous nephropathy progressing to stage 4 chronic kidney disease using low-dose rituximab: a longterm follow-up, Medicine (Baltimore), vol.97, p.11184, 2018. ,
High-dose rituximab and early remission in PLA2R1-related membranous nephropathy, Clin J Am Soc Nephrol, vol.14, pp.1173-1182, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02413171
Primary membranous nephropathy, Clin J Am Soc Nephrol, vol.12, pp.983-997, 2017. ,
Treatment of idiopathic membranous nephropathy, Nat Rev Nephrol, vol.9, pp.443-458, 2013. ,
Rituximab for idiopathic membranous nephropathy, Lancet, vol.360, pp.923-924, 2002. ,
Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy, Clin J Am Soc Nephrol, vol.2, pp.932-937, 2007. ,
Rituximab in idiopathic membranous nephropathy, J Am Soc Nephrol, vol.23, pp.1416-1425, 2012. ,
Rituximab treatment of idiopathic membranous nephropathy, Kidney Int, vol.73, pp.117-125, 2008. ,
Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference, Kidney Int, vol.95, pp.268-280, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02380922
Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate, Nephrol Dial Transplant, vol.19, pp.1142-1148, 2004. ,
Canadian Glomerulonephritis Study Group. A controlled trial of cyclosporine in patients with progressive membranous nephropathy, Kidney Int, vol.47, pp.1130-1135, 1995. ,
Urinary retinol binding protein is a marker of extent of interstitial kidney fibrosis, PLoS One, vol.9, p.84708, 2014. ,
Low-molecularweight proteins as prognostic markers in idiopathic membranous nephropathy, Clin J Am Soc Nephrol, vol.6, pp.2846-2853, 2011. ,
Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab, Kidney Int, vol.93, pp.1016-1017, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-02380978
Retreatment with rituximab for membranous nephropathy with persistently elevated titers of anti-phospholipase A2 receptor antibody, Kidney Int, vol.95, pp.233-234, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02380929
Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy, J Am Soc Nephrol, vol.28, pp.2729-2737, 2017. ,